Concepedia

Author

Veronica Juan

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Juan V., Juan, Veronica, V. Juan, Veronica Juan

21

Publications

757

Citations

11

H-Index

36

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)University of California, Santa CruzCzech Academy of Sciences, Institute of Molecular GeneticsUniversity of Chemistry and Technology, PragueAbbVie (United States)
VJ

About

Veronica Juan is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, natural sciences, and immunotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

278

2

Natural Sciences

3

3

196

3

Allergy

2

2

40

4

Engineering

1

1

69

5

Biochemistry

1

1

27

Veronica Juan

×

11

Publications

740

Citations

11

H-Index

YearCitations

Predicting Antibody Developability Profiles Through Early Stage Discovery Screening

Marc Bailly, Carl Mieczkowski, Veronica Juan,

mAbs

2020

206

BioPhi: A platform for antibody design, humanization, and humanness evaluation based on natural antibody repertoires and deep learning

David Příhoda, Jad Maamary, Andrew B. Waight,

mAbs

2022

179

Evidence for evolutionarily conserved secondary structure in the H19 tumor suppressor RNA

Veronica Juan

Nucleic Acids Research

2000

98

RNA Secondary Structure Prediction Based on Free Energy and Phylogenetic Analysis

Veronica Juan, Charles B. Wilson

Journal of Molecular Biology

1999

71

Deep mutational scanning of an antibody against epidermal growth factor receptor using mammalian cell display and massively parallel pyrosequencing

C.M. Forsyth, Veronica Juan, Yoshiko Akamatsu,

mAbs

2013

69

Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions

Pin‐Kuang Lai, Gaurav Ghag, Yao Yu,

mAbs

2021

28

Epitope mapping of monoclonal antibodies: a comprehensive comparison of different technologies

Xibei Dang, Lars Guelen, D. Lutje Hulsik,

mAbs

2023

27

Affinity and Cross-Reactivity Engineering of CTLA4-Ig To Modulate T Cell Costimulation

Zhenghai Xu, Veronica Juan, Alexander V. Ivanov,

The Journal of Immunology

2012

22

Preclinical characterization and clinical translation of pharmacodynamic markers for MK-5890: a human CD27 activating antibody for cancer immunotherapy

Lars Guelen, Thierry Fischmann, Jerelyn Wong,

Journal for ImmunoTherapy of Cancer

2022

16

Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational Evaluation

Mohammad Tabrizi, Divas Neupane, Sophia E. Elie,

The AAPS Journal

2019

13

Page 1